The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity

International Journal of Molecular Medicine

Volumn 25, Issue 1, 2010, Pages 129-136

  Park, Ki Hoon ^a   Shin, Dong Gu ^b   Kim, Jae Ryong ^a   Hong, Joo Heon ^c   Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

^b Yeungnam University Hospital   (South Korea)

^c Bio Industry Center   (South Korea)

Author keywords

Antioxidant; Cholesteryl ester transfer protein; Lipoproteins; Metabolic syndrome

Indexed keywords

ADIPONECTIN; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN C; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

APOLIPOPROTEIN C-III; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEINS; COPPER; HUMANS; IRON; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; OXIDATION-REDUCTION; PLASMA; SERUM AMYLOID A PROTEIN;

EID: 70549105817     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000322     Document Type: Article

References (30)

1. Chan DC, Watts GF, Barrett PH, Mamo JCL and Redgrave TG: Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 48: 278-283, 2002.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3213, 2002.
3. Holvoet P, Kritchevsky SB, Tracy RP, et al: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53: 1068-1073, 2004.
4. Ruotolo G and Howard BV: Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4: 494-500, 2002.
5. Suzuki T, Hirata K, Elkind MSV, et al: Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). Am Heart J 156: 405-410, 2008.
6. Rosolova H, Petrlova B, Simon J, Sifalda P and Sipova I: High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome. Med Sci Monit 14: CR411-CR415, 2008.
7. Gotto AM Jr and Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 43: 717-724, 2004.
8. Havel RJ, Eder HA and Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
9. Markwell MA, Haas SM, Bieber LL and Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 206-210, 1978.
10. Benzie IF and Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem 239: 70-76, 1996.
11. Esterbauer H, Striegl G, Puhl H and Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75, 1989.
12. Eckerson HW, Wyte CM and La Du BN: The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 35: 1126-1138, 1983.
13. Cho KH, Lee JY, Choi MS, Cho JM, Lim JS and Park YB: A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim Biophys Acta 1391: 133-144, 1998.
14. Maron DJ: The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 86: L11-L14, 2000.
15. De Souza JA, Vindis C, Hansel B, et al: Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197: 84-94, 2008.
16. Hansel B, Giral P, Nobecourt E, et al: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89: 4963-4971, 2004.
17. Cho KH, Park SH, Park JE, et al: The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome. Clin Biochem 41: 56-64, 2008.
18. Sarafidis PA and Nilsson PM: The metabolic syndrome: a glance at its history. J Hypertens 24: 621-626, 2006.
19. Puig JG and Martinez MA: Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20: 187-191, 2008.
20. Onat A, Uyarel H, Hergenc G et al: Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19: 1055-1062, 2006.
21. Palmer AM, Murphy N and Graham A: Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 173: 27-38, 2004.
22. Greene DJ, Skeggs JW and Morton RE: Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I. J Biol Chem 276: 4804-4811, 2001.
23. Cho KH, Shin DG, Baek SH and Kim JR: Myocardial infarction patients showed altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp Mol Med 28: 67-76, 2009.
24. Cabana VG, Lukens JR, Rice KS, Hawkins TJ and Getz GS: HDL content and composition in acute phase response in three species: triglyseride enrichment of HDL a factor in its decrease. J Lipid Res 37: 2662-2674, 1996.
25. Brown VW and Baginsky ML: Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46: 375-382, 1972.
26. Schayek E and Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266: 18259-18267, 1991.
27. Kawakami A, Osaka M, Tani M, et al: Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 118: 731-742, 2008.
28. Garin MC, Kalix B, Morabia A and James RW: Small dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 90: 2264-2269, 2005.
29. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Naval M and Fogelman AM: Antiinflammatory properties of HDL. Circ Res 95: 764-772, 2004.
30. Kontush A and Chapman J: Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342-374, 2006.